When do the patents on TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE expire, and when will generic TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Watson Labs	TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE	estradiol valerate; testosterone enanthate	INJECTABLE;INJECTION	085865-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Watson Labs	TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE	estradiol valerate; testosterone enanthate	INJECTABLE;INJECTION	085860-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: June 3, 2026

Market dynamics and financial trajectory for testosterone enanthate and estradiol valerate combination injectable

Executive summary: Testosterone enanthate plus estradiol valerate is a niche androgen-estrogen combination used for testosterone replacement and androgenic symptom control in settings where combined androgen-estrogen therapy is standard. Market demand is constrained by (1) prescriber preference for single-entity testosterone formulations, (2) safety and monitoring requirements tied to estrogen exposure, (3) regulatory and reimbursement variability by country, and (4) competition from newer testosterone replacement formats (gels, long-acting injectables) that reduce injection frequency and simplify monitoring. Financial performance is therefore typically characterized by low share, localized sales concentrations, and revenue sensitivity to channel access, substitution, and pricing actions rather than broad global scaling.

This analysis maps the likely market drivers and revenue trajectory using the product’s therapeutic class dynamics (TRT and hormone therapy) and the combination’s competitive position. It also outlines the business levers that determine commercial outcomes: formulary access, dosing schedule convenience, safety protocols, and manufacturing continuity.

No specific sales figures, net revenue, or regulatory marketing authorization details were provided for a named brand, country, or NDA/MAH. Without those inputs, the analysis is constrained to market-structure dynamics rather than company-level financial numbers.

What drives demand for testosterone enanthate and estradiol valerate injections?

Demand drivers (high level):

Clinical practice patterns: In markets where combination androgen-estrogen regimens are used for hypogonadism or gender-affirming hormone needs, sales can hold up even when single-entity TRT products dominate elsewhere.
Patient adherence to injection schedules: Enanthate and valerate are esterified depot hormones. Formulations that reduce injection frequency can outperform multi-dose regimens, but only if clinicians accept the monitoring burden.
Availability through local generics and channel penetration: Where the combination is off-patent and multiple manufacturers supply, price competition often compresses revenue per unit, with growth depending on volume and tenders.
Reimbursement and formulary rules: Coverage rules tied to “medical indication” language can materially shift uptake between hypogonadism and other hormone therapy use cases.

How does the combination’s estrogen exposure affect prescribing?

Estrogen in the regimen changes the risk and monitoring profile versus testosterone-only products:

Lab monitoring intensity (estradiol-related targets, hematocrit, lipids, liver enzymes where relevant).
Adverse-event management (fluid retention, breast tenderness, gynecomastia risk, thromboembolic risk considerations depending on patient factors).
Clinician comfort and guideline alignment: Many guidelines emphasize testosterone-first strategies with estradiol management only when needed. That can cap combination adoption in guideline-concordant systems.

What substitution risks exist versus testosterone-only TRT products?

Therapeutic substitution: Pharmacists and prescribers can steer patients to testosterone-only products to simplify monitoring and reduce estrogen-related adverse outcomes.
Convenience substitution: Long-acting testosterone injectables (and transdermals) can win because they reduce appointment burden and allow more flexible titration.
Tender dynamics: In government or payer tender systems, single-entity TRT often clears at lower administrative friction.

What market constraints limit growth for testosterone enanthate and estradiol valerate?

Key constraints:

Safety and monitoring requirements that raise clinician and payer friction.
Indication and labeling variability across countries, limiting promotional and reimbursement consistency.
Estrogen-related contraindications that narrow eligible patient populations.
Supply chain and manufacturing continuity risks typical for injectable sterile products.
Therapeutic trend toward individualized TRT rather than fixed combinations.

Are there indications where combination use still expands?

Expansion is most plausible where:

local protocols routinely use combined androgen-estrogen therapy,
there is limited access to testosterone-only formulations, or
payers subsidize combination products through bundled approvals.

How does pricing typically evolve for this hormone combination?

Typical pricing pathway in mature markets:

Initial launch pricing premium when exclusivity and limited suppliers exist.
Rapid price compression once multiple generic or biosimilar-like “drop-in” equivalents enter (even for small-molecule injectables, competitive substitution can be swift).
Tender-driven price setting that can reduce unit price even if volume holds.
Channel margin pressure as wholesalers and distributors renegotiate terms after tender cycles.

What pricing levers most affect revenue trajectory?

Tender frequency and pricing floors
Distributor contract renewals
Switching rates to testosterone-only products
Regulatory actions that restrict specific brands or batches

What is the competitive landscape for testosterone enanthate plus estradiol valerate?

Competitive set:

Testosterone-only TRT injectables (short and long-acting esters).
Testosterone gels and transdermals (higher adherence appeal, lower injection burden).
Oral testosterone or other delivery systems where available (less common in many regulated markets).
Other androgen-estrogen combinations if present locally.

How does the combination’s “formulary position” usually compare?

In highly guideline-driven systems, testosterone-only products are more likely to be preferred formulary options, making the combination a second-line or specialized option.
In protocol-driven systems that explicitly support fixed combination regimens, formulary placement can be stable but still exposed to generic substitution.

When does the product lose exclusivity, and how does that affect revenue?

A precise exclusivity timeline requires:

the specific brand name and jurisdiction,
the underlying marketing authorization and patent estate,
and whether the combination is in an early lifecycle or fully mature.

With no brand, regulator record, or patent data provided, this section cannot be stated accurately.

Business-typical pattern once exclusivity ends:

sales peak during exclusivity, followed by
generic entry-driven share erosion,
margin compression, and
revenue stabilization only if the product retains volume via tenders and clinician habit.

What generic entry risks exist for testosterone enanthate and estradiol valerate?

For injectable small molecules, generic risk typically comes via:

bioequivalence pathway without direct reliance on reference product patents after expiration,
authorized generics or parallel-supply in certain markets,
substitution at the pharmacy or prescriber level.

Where are entry barriers highest?

Sterile manufacturing and quality system maturity.
Local registration timelines.
Batch release constraints and shelf-life logistics.
Need for stability data for depot injectables in local conditions.

What signals predict faster erosion?

multiple approved suppliers in the same strength/pack,
frequent tender awards,
and aggressive pricing by new entrants.

How does FDA or Orange Book status affect market access in the U.S.?

A U.S.-specific Orange Book and FDA pathway analysis requires a known FDA product identifier (NDA/ANDA/BLA, strength, dosage form, and holder). Without those identifiers, no accurate Orange Book status, listing history, or regulatory exclusivity can be stated.

Market logic in the U.S. (general):

If the combination is not widely approved under current U.S. labeling, U.S. sales may be limited to specialty supply or import channels.
If an FDA-approved reference exists and patents are expired, generic entry risk becomes a primary revenue variable.

How do litigation and settlement dynamics typically influence this category?

For small-molecule hormone injectables, litigation affects revenue primarily via:

delayed generic approvals
injunction threats
carve-outs in settlement agreements
authorized generic timing

However, litigation events cannot be enumerated without jurisdiction, patent list, brand, and case docket details.

What manufacturing and supply dynamics influence financial trajectory?

Injectables are operationally sensitive:

Sterile fill-finish capacity
drug substance supply reliability
sterility assurance and batch release throughput
inspection history and compliance
packaging and cold-chain requirements where applicable

How do supply disruptions translate into revenue outcomes?

Short-term shortages can cause lost sales and substitution to alternatives.
Longer disruptions can reduce market share permanently if clinicians switch to entrenched substitutes.
Manufacturer downtime can also trigger allocation and increase unit costs.

What dosage, pack size, and dosing schedule dynamics matter commercially?

Revenue is driven by:

injection frequency (depot ester pharmacokinetics)
strength per mL and dosing conversion by prescriber protocol
unit pack economics (multi-dose vs single-dose configurations)
admin setting (clinic administered vs patient administered)

In the hormone category, even small changes in perceived dosing convenience can shift preference toward competitors.

How does this product likely perform financially across lifecycle stages?

Lifecycle model (category-based, not company-specific)

Launch/renewal phase: Higher unit price, lower competition, relatively stable share.
Maturity: More brands and generics, lower margins, more tender-driven volume.
Post-exclusivity: Share declines unless the product locks into formularies and maintains pricing discipline.
Consolidation: Fewer suppliers remain; revenue stabilizes but often at lower absolute profitability.

Financial trajectory drivers (what moves revenue up or down)

formulary inclusion changes,
payer reimbursement edits,
competitive pricing by newly approved suppliers,
supply continuity and batch availability,
safety signals leading to prescribing caution,
and shifting clinical preference toward testosterone-only strategies.

Key commercial scenarios for 3–5 year revenue outlook (structure-only)

Without brand-level data, the following scenarios are the business decision framework:

Stable specialized demand scenario
- Combination remains second-line in local protocols.
- Revenue holds due to tender inclusion and entrenched prescribing.
Share erosion scenario
- Competitors offer simpler regimens (testosterone-only).
- Unit price falls faster than volume can compensate.
Price-and-volume stabilization scenario
- Multiple suppliers normalize pricing.
- Sales stabilize at lower margin with predictable tender cycles.
Supply-driven volatility scenario
- Manufacturing disruptions create allocation or shortages.
- Revenue dips and share loss persists post-recovery.

Key Takeaways

Testosterone enanthate plus estradiol valerate is a niche but potentially persistent product where local clinical protocols support fixed combination hormone therapy.
Market growth is structurally constrained by estrogen-related monitoring burden and by clinician preference trends toward testosterone-only regimens.
Financial trajectory is typically governed by tender access, generic substitution intensity, and supply continuity rather than by premium pricing power.
In mature markets, revenue usually faces margin compression and share erosion risk after exclusivity windows close.
Any credible financial forecast needs brand- and jurisdiction-specific regulatory and sales data, since the combination’s availability and labeling can vary materially by country.

FAQs

1) Why do payers prefer testosterone-only therapies over testosterone enanthate plus estradiol valerate?

Because testosterone-only regimens reduce estrogen-related monitoring complexity and broaden eligible patient pathways under common payer policy frameworks.

2) What determines whether the combination injectable gains formulary placement?

Protocol inclusion, demonstrated clinical acceptance, ability to manage estrogen-related monitoring, and competitive pricing versus single-entity TRT alternatives.

3) Does tender pricing typically reduce revenue or only margins for hormone injectables?

It often reduces both unit price and profitability; volume can offset revenue only if substitution risk is limited.

4) How does a manufacturing disruption in sterile injectables impact long-term share?

Loss of access can cause sustained prescribing shifts to alternative products, so share may not fully recover even after supply normalizes.

5) Are safety-monitoring requirements a major commercial headwind for combination hormone injectables?

Yes. Higher monitoring frequency increases administrative friction for clinics and payers, which can suppress uptake relative to simpler regimens.

References

FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (U.S. FDA). https://www.accessdata.fda.gov/scripts/cder/daf/
FDA. Drugs@FDA. (U.S. FDA). https://www.accessdata.fda.gov/scripts/cder/daf/
European Medicines Agency. Human medicines: public assessment reports and EPARs. (EMA). https://www.ema.europa.eu/en/human-regulatory/overview
World Health Organization. WHO model lists and hormone therapy references (category background). https://www.who.int/

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	118
DailyMed Link:	TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE at DailyMed

TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE Drug Patent Profile

When do Testosterone Enanthate And Estradiol Valerate patents expire, and when can generic versions of Testosterone Enanthate And Estradiol Valerate launch?

AI Deep Research

Questions you can ask:

Summary for TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE

US Patents and Regulatory Information for TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE